Key result
Pharmacologic inhibition of neprilysin with LBQ657 significantly reduced renal Ang-(1-7) levels by 53.1% in mice, demonstrating its role as a major mediator of alternative renin-angiotensin-system activation.
Why the study?
Does neprilysin mediate alternative renin-angiotensin-system activation and Ang-(1-7) formation in murine and human kidneys?
Does neprilysin mediate alternative renin-angiotensin-system activation and Ang-(1-7) formation in murine and human kidneys?
Answers are grounded in this paper and cite their sources.
Neprilysin is a major mediator of alternative RAS activation and Ang-(1-7) formation in the kidney, providing mechanistic insights into the effects of ARNI therapy in heart failure.
Cardiovascular and renal pathologies are frequently associated with an activated renin-angiotensin-system (RAS) and increased levels of its main effector and vasoconstrictor hormone angiotensin II (Ang II). Angiotensin-converting-enzyme-2 (ACE2) has been described as a crucial enzymatic player in shifting the RAS towards its so-called alternative vasodilative and reno-protective axis by enzymatically converting Ang II to angiotensin-(1-7) (Ang-(1-7)). Yet, the relative contribution of ACE2 to Ang-(1-7) formation in vivo has not been elucidated. Mass spectrometry based quantification of angiotensin metabolites in the kidney and plasma of ACE2 KO mice surprisingly revealed an increase in Ang-(1-7), suggesting additional pathways to be responsible for alternative RAS activation in vivo. Following assessment of angiotensin metabolism in kidney homogenates, we identified neprilysin (NEP) to be a major source of renal Ang-(1-7) in mice and humans. These findings were supported by MALDI imaging, showing NEP mediated Ang-(1-7) formation in whole kidney cryo-sections in mice. Finally, pharmacologic inhibition of NEP resulted in strongly decreased Ang-(1-7) levels in murine kidneys. This unexpected new role of NEP may have implications for the combination therapy with NEP-inhibitors and angiotensin-receptor-blockade, which has been shown being a promising therapeutic approach for heart failure therapy.
No takes yet. Share an insight, caveat, or question.
Domenig et al. (2016) studied Renin-Angiotensin-System Activation. Neprilysin inhibition (LBQ657) vs. Vehicle was evaluated on Renal Ang-(1-7) levels (53.1% reduction, p=0.026). Pharmacologic inhibition of neprilysin with LBQ657 significantly reduced renal Ang-(1-7) levels by 53.1% in mice, demonstrating its role as a major mediator of alternative renin-angiotensin-system activation.
Synapse has enriched 10 related papers. Consider them for comparative context: